Faecal microbiome and serum metabolomics: potential biomarkers for type 2 diabetes.

T2D patients exhibited 20 differential gut microbiome taxa compared to healthy controls.

• Fecal samples from 30 T2D patients and 30 healthy controls (HCs) were analyzed using 16S rRNA sequencing.
• 20 differential microbiomes were identified in the gut of T2D patients versus HCs.
• Alpha and beta diversity indices including Chao1, Shannon, and PCoA were calculated to assess microbial diversity and community structure.

T2D patients exhibited 30 differential serum metabolites compared to healthy controls.

• Serum metabolites were detected by UHPLC-MS/MS from 30 T2D patients and 30 healthy controls.
• 30 differential metabolites were identified in the blood of T2D patients versus HCs.
• Differential metabolites were integrated to identify potential biomarkers.

A significant correlation was observed between gut microbiota and serum metabolomic profiles in T2D patients.

• The correlation between gut microbiota and serum metabolomics reflected the influence of the microbiota on metabolic activity.
• Both fecal microbiome composition and serum metabolite profiles were measured in the same cohort of 30 T2D patients and 30 HCs.
• The integrated analysis of gut microbes and metabolites allowed clear distinguishability between T2D and HC groups.

Random forest models built on gut microbiota and serum metabolites achieved excellent diagnostic performance for T2D.

• The random forest model using gut microbiota achieved an AUC value of 0.9764.
• The random forest model using serum metabolites achieved an AUC value of 0.9823.
• Random forest modeling was used for predictive analysis to investigate and validate the importance of specific gut microbial genera.
• T2D and HC groups were described as 'clearly distinguishable' based on differences in gut microbes and metabolites.

The study characterized the relationship between gut microbiome and serum metabolome in T2D using a combined multi-omics approach.

• The study collected both fecal and serum samples from 30 T2D patients and 30 healthy controls.
• 16S rRNA sequencing was used for fecal microbiome composition analysis and UHPLC-MS/MS was used for serum metabolite detection.
• The authors noted that 'the relationship between gut microbiota and serum composition in T2D has not been fully characterized' prior to this study.
• The study aimed to provide 'a comprehensive profile of changes in the microbiome and serum metabolomics' relevant to T2D diagnosis and treatment.